Tesamorelin
Clinical evidence — Human trial data existsWhat it is
A GHRH analogue approved in some countries to reduce visceral fat in specific patient groups, with human trial data.
Tesamorelin is a GHRH analogue approved in some countries to reduce visceral fat in a specific patient group, with supporting human trial data.
Research context
Studied in relation to:
- Visceral-fat research
Points in its favour in the literature:
- Approved for a defined indication
- Human trial evidence
Caveats and unknowns:
- Approved only for specific groups
- Research-grade differs from licensed drug
- Prohibited in sport
Handling & reference data
Route in published researchSubcutaneous injection is the route most commonly described in the research literature. Once daily.
Reported half-lifeshort
Published clinical / research context (not instructions)The approved-indication dose is ~2 mg once daily.
Storage (lyophilised)Lyophilised (freeze-dried) powder: refrigerate at 2–8 °C short-term, or freeze at −20 °C or below for long-term storage. Keep sealed and out of light.
Reconstituted solutionOnce reconstituted: keep refrigerated (2–8 °C), protect from light, do not freeze. With bacteriostatic water, commonly used within ~4 weeks; with plain sterile water, within ~24–48 h.
Worked reconstitution example (arithmetic only)e.g. 5 mg vial + 2 mL → 2.5 mg/mL.
Available research formats
| Strength | SKU |
|---|---|
| 5mg | TSM5 |
| 10mg | TSM10 |
| 20mg | TSM20 |
Current pricing (THB with USD/GBP conversion) is shown live in the catalogue, which also has a transparent U-100 reconstitution calculator.